Skip to content

Dosing patterns of labetalol for managing blood pressure among patients with acute cerebral hemorrhage and spontaneous subarachnoid hemorrhage

Dosing patterns of labetalol for managing blood pressure among patients with acute cerebral hemorrhage and spontaneous subarachnoid hemorrhage

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200501001
Enrollment
282
Registered
2020-05-01
Start date
2020-06-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In Thailand&#44

Interventions

(5&#45
X&#45
X) A bolus dose of IV labetalol 5 mg will be initiated. Then a bolus dose of IV labetalol 5 mg can be given after 15 minutes if the subsequent SBP is >=140 mmHg. Then two more bolus doses of IV labeta
20) can be given&#44
every 15 minutes judged by attending physician(s) if the SBP is still >=140 mmHg.,(10&#45
X) A bolus dose of IV labetalol 10 mg will be initiated. Then a bolus dose of IV labetalol 10 mg can be given after 15 minutes if the subsequent SBP is >=140 mmHg. Then two more bolus doses of IV lab
20) can be given every 15 minutes judged by attending physician(s) if the SBP is still >=140 mmHg.
Active Comparator Drug,Active Comparator Drug
Labetalol 5 mg,Labetalol 10 mg

Sponsors

Great Eastern Drug Co., Ltd.
Lead Sponsor
Great Eastern Drug Co.&#44
Collaborator
Ltd.
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years 2. Have diagnosis of spontaneous non-traumatic SAH or ICH confirmed by head computerized tomography 3. Have systolic blood pressure 180 mmHg 4. Need intravenous antihypertensive drug for blood pressure management 5. agree to consent

Exclusion criteria

Exclusion criteria: 1. Received any intravenous antihypertensive drug(s) before the enrollment 2. Current known pregnancy and parturition 3. Known hypersensitivity to labetalol or any ingredient in the formulation 4. Has one of these contraindications: 4.1 Obstructive airway disease (e.g.&#44; bronchial asthma&#44; COPD) 4.2 Heart rate <=60 bpm 4.3 2nd and 3rd degree heart block 4.4 uncontrolled heart failure 4.5 metabolic acidosis 4.6 severe peripheral arterial disease 5. Inappropriate candidate considered by attending physician(s)

Design outcomes

Primary

MeasureTime frame
The rate of achievement at less than 140 mmHg after labetalol administration predose&#44; 15&#44; 30&#44; 45&#44; 60&#44; 75&#44;90&#44;105&#44; 120 min&#44; ...&#44; 24 h blood pressure

Secondary

MeasureTime frame
Time to achieving SBP less than 140 mmHg predose&#44; 15&#44; 30&#44; 45&#44; 60&#44; 75&#44;90&#44;105&#44; 120 min&#44; ...&#44; 24 h blood pressure ,Total dosage of achieving SBP less than 140 mmHg at the end of the study dose level,Adverse events such as bradycardia and hypotension at the end of the study symtom,Rescued medication for managing blood pressure at the end of the study drug name

Countries

Thailand

Contacts

Public ContactPrajak Srirabheebhat

Faculty of Medicine Siriraj Hospital&#44; Mahidol University

pj_saesue@hotmail.com+66 (0) 2 4198003

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026